The Nasdaq Composite and the S&amp;P 500 were lower on Monday as a bout of profit-taking squeezed the richly-valued technology sector.Technology stocks have led a record-setting rally on Wall Street, helped largely by strong quarterly earnings. The S&amp;P 500 technology index has risen 18.5% this year and is on track to register its best yearly performance since 2014.However, the index tumbled 2.7% on Friday, sparked by a sharp drop in Apple shares amid reports that the company is using slower modems in upcoming iPhones, compared with those used by rivals.Shares of the world&#8217;s most valuable publicly-listed company were off 3.5% at $143.52 on Monday and weighed the most on all three main indexes.The S&amp;P technology sector was down 1.34% due to declines in closely watched technology stocks, including those of Microsoft, Facebook, Netflix and Alphabet.&#8220;We&#8217;re starting to question valuations of technology (stocks) at these levels and investors are trying to jockey their way around this thought process,&#8221; said Andre Bakhos, managing director at Janlyn Capital in Bernardsville, New Jersey.Wall Street&#8217;s major indexes hit all-time highs on Friday, driven by banks and energy stocks but those gains were offset by the tech selloff later in the day.Financials rose 0.5% on Monday, while energy was up 1.3%, helping cushion some of the impact from the tech rout.At 9:40am ET (1340 GMT), the Dow Jones Industrial Average was down 16.93 points, or 0.08%, at 21 255.04.The S&amp;P 500 was down 5.2 points, or 0.21%, at 2 426.57 and the Nasdaq Composite was down 62.95 points, or 1.01%, at 6 144.97.Shares of General Electric rose 4.8% to $29.29 after the company said Jeff Immelt would retire as chief executive and would be replaced by John Flannery, the head of GE healthcare, ending a years-long succession plan. GE was the top stock on the S&amp;P 500.Coherus BioSciences tumbled 30.2% to $14.40 after the FDA denied the approval of its biosimilar for Amgen&#8217;s Neulasta, which fights infections in cancer patients. Amgen was up 1.5 at $166.61.Advancing issues outnumbered decliners on the NYSE by 1 635 to 954. On the Nasdaq, 1 206 issues rose and 1 166 fell.The S&amp;P 500 index showed 28 new 52-week highs and 11 new lows, while the Nasdaq recorded 82 new highs and 70 new lows.